BCHE and early-onset autosomal dominant Alzheimer disease: A novelty in terms of evaluation of hop cone biofunctionality is the determination of a marker related to the activity of AChE and BChE inhibitors used in the treatment of neurodegenerative diseases, especially in Alzheimer’s disease [39,40].